Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

PD-L1 antibody (Extracellular Domain)

PD-L1 Reactivity: Human FACS, IHC (p) Host: Mouse Monoclonal 27A2 unconjugated
Catalog No. ABIN1449244
  • Target See all PD-L1 Antibodies
    PD-L1 (CD274 (PD-L1))
    Binding Specificity
    • 29
    • 16
    • 15
    • 13
    • 11
    • 8
    • 8
    • 7
    • 5
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Extracellular Domain
    Reactivity
    • 165
    • 114
    • 62
    • 6
    • 5
    • 5
    • 5
    • 1
    • 1
    Human
    Host
    • 131
    • 53
    • 19
    • 4
    • 2
    • 1
    Mouse
    Clonality
    • 113
    • 95
    • 2
    Monoclonal
    Conjugate
    • 91
    • 15
    • 14
    • 11
    • 8
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    This PD-L1 antibody is un-conjugated
    Application
    • 133
    • 102
    • 56
    • 40
    • 36
    • 28
    • 17
    • 15
    • 14
    • 12
    • 10
    • 7
    • 6
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Specificity
    This antibody reacts with human CD274 antigen.
    Purification
    Protein A agarose
    Immunogen
    Recombinant human PD-L1 extracellular domain
    Clone
    27A2
    Isotype
    IgG2b
    Top Product
    Discover our top product PD-L1 Primary Antibody
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Concentration
    1.0 mg/mL
    Buffer
    PBS containing 50 % glycerol, pH 7.2. No preservative is contained.
    Preservative
    Without preservative
    Handling Advice
    Avoid repeated freezing and thawing.
    Storage
    -20 °C
    Storage Comment
    Upon receipt, store (in aliqouts) at -20 °C.
  • Gadiot, Hooijkaas, Kaiser, van Tinteren, van Boven, Blank: "Overall survival and PD-L1 expression in metastasized malignant melanoma." in: Cancer, Vol. 117, Issue 10, pp. 2192-201, (2011) (PubMed).

    Hino, Kabashima, Kato, Yagi, Nakamura, Honjo, Okazaki, Tokura: "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma." in: Cancer, Vol. 116, Issue 7, pp. 1757-66, (2010) (PubMed).

    Schuchmann, Meyer, Distler, von Stebut, Kuball, Schnürer, Wölfel, Theobald, Konur, Gregor, Schreiner, Huber, Galle, Otto, Herr: "The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation." in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 8, Issue 11, pp. 2434-44, (2008) (PubMed).

    Fancke, Suter, Hochrein, OKeeffe: "M-CSF: a novel plasmacytoid and conventional dendritic cell poietin." in: Blood, Vol. 111, Issue 1, pp. 150-9, (2008) (PubMed).

    Hamanishi, Mandai, Iwasaki, Okazaki, Tanaka, Yamaguchi, Higuchi, Yagi, Takakura, Minato, Honjo, Fujii: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 9, pp. 3360-5, (2007) (PubMed).

    Vega, Jazirehi, Huerta-Yepez, Bonavida et al.: "Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and ..." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 4, pp. 2174-83, (2005) (PubMed).

  • Target
    PD-L1 (CD274 (PD-L1))
    Alternative Name
    CD274 / PDL1 (PD-L1 Products)
    Synonyms
    B7-H antibody, B7H1 antibody, PD-L1 antibody, PDCD1L1 antibody, PDCD1LG1 antibody, PDL1 antibody, A530045L16Rik antibody, B7h1 antibody, Pdcd1l1 antibody, Pdcd1lg1 antibody, Pdl1 antibody, RGD1566211 antibody, CD274 molecule antibody, CD274 antigen antibody, programmed cell death 1 ligand 2 antibody, CD274 antibody, Cd274 antibody, PDCD1LG2 antibody
    Background
    Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was identified by searching for mo lecules that share homology with the immunogloblin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-Ig were activated, proliferation and production of IFN- γ GM-CSF and IL-10 from the T cells were enhanced. The role of PD-L1 is now debatable.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1
    Gene ID
    29126
    NCBI Accession
    NP_054862
    UniProt
    Q9NZQ7
    Pathways
    Cancer Immune Checkpoints
You are here:
Support